December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

5.720 USD -0.380 (-6.23%)
Official Closing Price Updated: 5:02 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Adaptimmune Ther Ads

< Previous 1 2 3 4 5 6 7 Next >
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma... 
From GlobeNewswire News Releases
Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol — Discovering
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK Telecom Co., Ltd.... 
From GlobeNewswire News Releases
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago,... 
From GlobeNewswire News Releases
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2018, as well as provided a business... 
From GlobeNewswire News Releases
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before the open... 
From GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, Alder Biopharma, and Alexion Pharma
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ADAP, AKBA, ALDR, and ALXN which can be accessed for free by signing up to... 
From PR Newswire
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the annual... 
From GlobeNewswire News Releases
Adaptimmune Announces Changes to Board of Directors
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned transition, John Furey has been appointed as an independent Non-Executive... 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia S.A, Adaptimmune Therapeutics, Radware, Mimecast, and Bandwidth — New Horizons, Emerging Trends, and
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brookfield Property... 
From GlobeNewswire News Releases
Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the... 
From GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2017, as well as provided a... 
From GlobeNewswire News Releases
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors 
From GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Methanex, YPF Sociedad Anonima, Adaptimmune Therapeutics, Horizon Pharma, Changyou, and China Yuchai International — Discovering Underlying Factors of In
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Methanex Corporation... 
From GlobeNewswire News Releases
Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2017 and provide a general business update... 
From GlobeNewswire News Releases
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity 
From GlobeNewswire News Releases
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one... 
From GlobeNewswire News Releases
Paul Stead Joins Adaptimmune as Vice President of Business Development
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of... 
From GlobeNewswire News Releases
Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study1 of NY?ESO SPEAR T-cell therapy in multiple myeloma... 
From GlobeNewswire News Releases
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study1 of NY?ESO SPEAR T-cell therapy in multiple myeloma... 
From GlobeNewswire News Releases
Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, is presenting two trials in progress posters summarizing study designs for ongoing clinical trials with MAGE-A4... 
From GlobeNewswire News Releases
NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, released updated data from the ongoing pilot study of NY?ESO SPEAR T-cells in synovial sarcoma, as well as an... 
From GlobeNewswire News Releases
Adaptimmune marks Official Opening of U.K. Headquarters
Flagship Facility is new Base for U.K. Research and Development Operations 
From GlobeNewswire News Releases
Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual meeting November... 
From GlobeNewswire News Releases
Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that new data will be presented in an oral presentation and a trial in progress poster at the... 
From GlobeNewswire News Releases
Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended September 30, 2017. 
From GlobeNewswire News Releases
Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended September 30, 2017 before the open of the U.S. markets on... 
From GlobeNewswire News Releases
Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has joined the Company as Vice President of Communications and Investor... 
From GlobeNewswire News Releases
James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will participate in the upcoming Leerink... 
From GlobeNewswire News Releases
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and... 
From GlobeNewswire News Releases
Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.